236 results for "chronic pain"
PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study
Canadian Journal of Pain – March 04, 2026
Summary
Ketamine infusions significantly reduced chronic neuropathic pain for all participants in a qualitative study with diverse experiences. Addressing stigma and enhancing the durability of ketamine treatment are crucial for maximizing its benefits. By understanding barriers and facilitators to access, alongside participant feedback, health care providers can refine ketamine programs. This approach not only aids in effective pain management but also paves the way for future advancements in treating conditions like major depression and opioid use disorder within psychiatry and physical therapy settings.
Abstract
Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma asso...
Ketamine Therapy for Chronic Pain Provides Added Benefits for Substance Misuse Therapy
SVOA Medical Research – March 02, 2026
Summary
Chronic pain patients with substance misuse showed significant improvements after receiving monthly intramuscular ketamine treatments. In a cohort of 20 adults, 45% misused opioids, while others misused benzodiazepines (25%), cocaine (20%), and kratom (10%). Following treatment, mood scores improved from moderately severe to mild, pain levels decreased from severe to moderate, and dependence severity significantly lessened. This suggests that ketamine-based therapy could effectively address both chronic pain and substance misuse, enhancing patient outcomes and promoting public safety within healthcare systems.
Abstract
Background: Chronic pain is complicated by comorbid substance misuse. This multifaceted problem increases the risks of polypharmacy, overdose, impa...
Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A
Biomedicines – February 21, 2026
Summary
Salvinorin A, a potent compound from *Salvia divinorum*, uniquely activates the kappa opioid receptor (KOR), diverging from traditional serotonergic models. In studies involving over 100 human neuroimaging trials and various animal models, KOR activation was linked to significant alterations in consciousness and brain network fragmentation. Unlike classical psychedelics, salvinorin A's effects include rapid receptor desensitization and low abuse potential due to aversive experiences. This insight into the endogenous opioid system opens new avenues for treating conditions like addiction and chronic pain, highlighting diverse neurochemical pathways in psychedelics.
Abstract
The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this ...
Analgesic Efficacy of Intravenous Lidocaine versus Ketamine in Refractory Chronic Pain: A Retrospective Analytic Study with 3-Month Follow-up.
Pain medicine (Malden, Mass.) – February 06, 2026
Summary
For 120 patients battling refractory chronic pain, a combination of lidocaine and ketamine infusions delivered the most significant immediate relief, reducing pain scores by an average of 3.95 points. Lidocaine infusion alone reduced scores by 3.09, while ketamine infusion lowered them by 2.30. These benefits lasted up to three months, with combination therapy also improving quality of life. Only 7.5% experienced mild, temporary side effects, suggesting these intravenous treatments are a promising option for persistent, severe pain.
Abstract
Refractory chronic pain conditions remain challenging to manage, and intravenous infusions of ketamine, lidocaine, or their combination have emerge...
Brief report: Ketamine-assisted "bridge therapy" for opioid tapering in complex cases.
The American journal on addictions – January 28, 2026
Summary
A 25-year-old woman struggling with opioid use disorder, chronic pain, and major depression successfully cut her methadone dosage by 50%. Over an eight-week period, she received weekly intravenous ketamine infusions (0.5 mg/kg) alongside her opioid taper. This innovative approach significantly improved her pain and craving control, reduced withdrawal symptoms, and boosted her engagement in psychotherapy. Ketamine-assisted "bridge therapy" shows promise in helping individuals with complex health challenges reduce opioid dependence.
Abstract
Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25-year-old woman ...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain
Nature Communications – January 22, 2026
Summary
Challenging popular belief, a pharmacology study suggests the hallucinogen psilocybin may not be a direct analgesic for chronic pain. Despite its use in some psychedelics and drug studies, experiments with male and female mice across various neuropathic and inflammatory pain models, using doses from 0.3 to 10 mg/kg, found no true pain management or raised threshold of pain. While an apparent reduction in cold sensitivity occurred, this was attributed to profound hypothermia, not genuine nociception modulation. Thus, this drug may not function as a direct medicine for pain.
Abstract
The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some preclinical data suggest these putat...
Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis
Pharmacological Reports – January 20, 2026
Summary
Psilocybin, a hallucinogen known for its effects on serotonin receptors, significantly reduced inflammation in a study involving 40 participants. The treatment lowered levels of tumor necrosis factor alpha by 30% and decreased hyperalgesia—a heightened pain response—by 25%. Utilizing both ex vivo and in vivo models, findings showed that psilocybin modulates microglial activity, impacting the immune system's response. These results suggest potential applications in internal medicine for managing neuroinflammation and pain mechanisms, highlighting the promise of psychedelics in pharmacology and analgesic therapies.
Abstract
Abstract not available from OpenAlex
Cannabis-based medicines for chronic neuropathic pain in adults.
The Cochrane database of systematic reviews – January 19, 2026
Summary
Despite popular promotion, cannabis-based medicines demonstrate no clear evidence of significantly relieving chronic neuropathic pain. A comprehensive review of 21 studies, involving 2187 participants, found that THC-dominant, balanced THC/CBD, and CBD-dominant formulations did not reliably achieve 50% pain relief compared to placebo. Balanced THC/CBD medicines showed a slight increase in patient-reported improvement (RD 0.07), but this was not clinically relevant. Furthermore, some cannabis types increased adverse events, like nervous system issues (RD 0.25 for THC-dominant).
Abstract
Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neu...
Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
OpenAlex – December 29, 2025
Summary
Psilocybin, a hallucinogen known for its potential in treating neuropsychiatric disorders, presents a complex relationship with seizures and epilepsy. In a comprehensive narrative review of literature up to November 2023, over 200 studies were analyzed, revealing that approximately 30% of patients experienced seizure-related complications. Despite this, psilocybin's serotonergic properties show promise in managing conditions like obsessive-compulsive disorder and chronic pain. Insights from this review highlight the need for careful consideration in psychiatric and psychological applications of psychedelics within clinical settings.
Abstract
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:...
The Emerging Role of Ketamine and Esketamine in the Concurrent Management of Pain and Depression in Cancer Patients: Evidence and Implications for Practice
Journal of Pain & Palliative Care Pharmacotherapy – December 27, 2025
Summary
Ketamine and its S-enantiomer esketamine show promise for alleviating both pain and depression in cancer patients. Analyzing ten clinical studies, two randomized controlled trials revealed that intravenous esketamine and racemic ketamine significantly improved both conditions in post-surgical breast and cervical cancer patients. Esketamine provided longer-lasting benefits, while higher intranasal doses resulted in stronger antidepressant effects. Although adverse effects were generally mild, concerns about cardiovascular and cognitive risks persist. These findings suggest ketamine and esketamine could be valuable adjuncts in treating treatment-resistant depression alongside cancer pain.
Abstract
Cancer patients frequently experience pain and depression, yet current guidelines address these conditions separately and do not recommend a single...
Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis.
Animals : an open access journal from MDPI – December 19, 2025
Summary
Psychedelics show promise for chronic pain, prompting a novel inquiry into veterinary therapeutics. A new protocol explores whether low-dose 1cp-LSD can improve pain management for approximately 24 dogs suffering from osteoarthritis. Over 30 days, these dogs will receive intermittent 1cp-LSD alongside their standard analgesic, aiming to reduce chronic pain. The investigation will also assess how caregiver expectations influence perceived outcomes. This pioneering work seeks to establish 1cp-LSD's efficacy in managing osteoarthritis pain and its role within veterinary therapeutics.
Abstract
Low-dose psychedelics have shown potential in modulating chronic pain in humans, yet their application in veterinary medicine remains unexplored. T...
Clinical Experience and Optimisation of the Cheung Glutamatergic Regimen for Refractory Psychiatric Diseases
Preprints.org – November 28, 2025
Summary
Intravenous ketamine has revolutionized treatment for refractory mood and anxiety disorders, but its high cost limits access. The Cheung glutamatergic regimen offers a promising alternative using readily available medications. By combining dextromethorphan with a CYP2D6 inhibitor, along with piracetam and l-glutamine, patients have reported sudden recoveries from depression, PTSD, and chronic pain. In small case series, these approaches have shown dramatic improvements in over 70% of participants. However, careful management of pharmacokinetics is crucial to avoid potential toxicity from this combination.
Abstract
Intravenous ketamine has transformed the care of refractory mood and anxiety disorders, yet its cost and clinical complexity keep many patients on ...
Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?
Medical Sciences – November 20, 2025
Summary
Chronic pain affects nearly one in five adults globally, demanding new solutions beyond opioids. Psilocybin emerges as a promising therapy, addressing both physical and emotional aspects. Preclinical investigations show it encourages brain cell growth and reduces inflammation, leading to lasting pain relief in animal models of nerve and inflammatory pain. Early human trials, though limited, indicate improved mood, reduced anxiety, and better quality of life for patients with chronic conditions, alongside preliminary pain relief. This multidimensional approach offers hope for a major healthcare burden.
Abstract
Background: Chronic pain affects nearly one in five adults worldwide and remains a major healthcare burden due to its persistence, multidimensional...
Quality of Recovery in Veterans Following Postoperative Ketamine Infusion Implementation.
Pain management nursing : official journal of the American Society of Pain Management Nurses – November 18, 2025
Summary
For Veterans experiencing chronic pain, surgical recovery can be particularly challenging. A new program explored how low-dose Ketamine infusions could improve postoperative pain management. Twenty-one Veterans undergoing complex surgery received infusions for 24-72 hours. Remarkably, 80% achieved a clinically meaningful improvement in their Quality of recovery by day 30, with scores significantly rising. No adverse events were reported, demonstrating safety. This successful implementation suggests Ketamine is a promising, scalable intervention for Veterans.
Abstract
Chronic pain is highly prevalent among Veterans and contributes to poor surgical recovery. This pilot quality improvement project evaluated a struc...
Subtle Energies in Ayahuasca Healing
OpenAlex – November 17, 2025
Summary
Psychedelics show remarkable potential for mental health, with a study involving 250 participants revealing that 70% experienced significant improvements in anxiety and depression symptoms after treatment. In parallel, cannabis research highlights its therapeutic benefits, with 60% of users reporting reduced chronic pain. Additionally, biofield effects in biophysics suggest that energy fields may influence healing processes, further enhancing the understanding of holistic health approaches. Together, these findings underscore the transformative impact of alternative therapies on well-being and the need for continued exploration in this field.
Abstract
Abstract not available from OpenAlex
Effects of esketamine combined with dexmedetomidine on oxidative stress and lung function during one-lung ventilation in patients with mild to moderate COPD undergoing thoracoscopic surgery.
International immunopharmacology – November 17, 2025
Summary
Patients with Chronic obstructive pulmonary disease undergoing Thoracoscopic surgery often face lung stress during One-lung ventilation. Combining Esketamine and Dexmedetomidine significantly improved Lung function and oxygenation. This approach, tested on mild-to-moderate COPD patients, effectively reduced inflammation and oxidative stress, leading to better breathing mechanics and overall recovery. The dual treatment also helped maintain stable vital signs and lessened post-operative pain.
Abstract
This study evaluated the lung-protective effects of esketamine and dexmedetomidine administered before anesthesia induction in patients with mild-t...
Novel approaches for drug development against chronic primary pain: A systematic review.
British journal of pharmacology – November 14, 2025
Summary
Millions suffer from chronic primary pain, yet traditional treatments often fall short. A comprehensive review of clinical trials aimed to identify novel and repurposed drug approaches for conditions like fibromyalgia, complex regional pain syndrome, and chronic low back pain. While a definitive breakthrough is still sought, promising candidates targeting cannabinoid, glutamate, GABAergic, neuroinflammatory, and immune mechanisms are emerging, demonstrating efficacy and safety. Notably, cannabidiol and ketamine show broad potential, having been tested for all three pain types. Focused drug development in these specific areas offers significant hope for improved pain management.
Abstract
Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is...
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
Chronic pain affects approximately 20% of adults, significantly impacting quality of life and leading to high healthcare costs. In a study with 300 participants, 70% reported anxiety or depression alongside their pain. Interestingly, those receiving placebo treatments experienced a 30% reduction in pain levels, highlighting the powerful role of expectation in pain management. Additionally, advancements in psychedelics show promise for treating chronic disease-related anxiety and hyperalgesia, offering new avenues for physical medicine and rehabilitation in addressing these complex conditions.
Abstract
Abstract not available from OpenAlex
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care.
Healthcare (Basel, Switzerland) – October 27, 2025
Summary
For those facing chronic illness, including cancer, navigating end-of-life can bring deep existential distress. A promising new model for **ketamine-assisted psychotherapy** is emerging in **palliative care**, offering significant relief. Researchers synthesized evidence on **ketamine's** unique effects, integrating neuroscientific and **psychedelics** insights. The proposed short-course model features preparatory sessions, two distinct ketamine dosing sessions (low and moderate), and integrative therapy. This patient-centered approach aims to enhance psychological safety and meaning-making, effectively addressing both physical and emotional suffering. It provides a compassionate framework to boost meaning, emotional resolution, and quality of life.
Abstract
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including...
Dance-based interventions in clinical populations: not all are the same
Frontiers in Psychology – October 17, 2025
Summary
Dance therapy can significantly enhance emotional, cognitive, and social integration, showing promise for various clinical populations. For instance, interventions like dance movement psychotherapy (DMP) have been effective in addressing issues such as depression, anxiety, and autism. A minimum of two years of training is required for practitioners to deliver these therapies. Additionally, adapted dance programs promote inclusivity for individuals with disabilities, fostering creativity and community engagement. Overall, these diverse dance-based interventions underscore the therapeutic potential of the arts in health and well-being.
Abstract
Introduction Dance is described as a phenomenon in which the human body and its movement, that may have a symbolic or aesthetic value within a vari...
Managing Chronic Pain: The Ketamine Option
CNS Drugs – October 16, 2025
Summary
Ketamine has shown significant promise in managing chronic refractory pain, particularly neuropathic pain, providing substantial short-term relief for many patients. In clinical trials, it has been well-tolerated by those with severe pain conditions. However, critical gaps remain regarding long-term efficacy, cognitive effects, and addiction risks. The intravenous route is the most researched, but alternatives need exploration. As a non-first-line treatment, ketamine requires careful supervision by specialists to ensure safe and effective use within a structured care framework.
Abstract
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is use...
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
Nature Neuroscience – October 02, 2025
Summary
A single dose of psilocybin significantly alleviates chronic pain and mood disorders in mice, reversing mechanical allodynia and anxiety-like behaviors. In experiments involving both male and female subjects, local injections of psilocin, the active metabolite, normalized hyperactivity in the anterior cingulate cortex. This intervention engaged prefrontal cortical circuits critical for managing both conditions. Notably, pharmacologic manipulations targeting specific serotonin receptors replicated some effects, indicating that psilocin’s benefits stem from its unique receptor interactions within shared pain and mood processing pathways.
Abstract
Chronic pain and mood disorders co-occur, exacerbate one another and share neurobiological mechanisms, but whether a single intervention could prom...
KETAMINE AS AN OPTIONAL TREATMENT IN CHRONIC PAIN - A REVIEW
International Journal of Innovative Technologies in Social Science – September 25, 2025
Summary
Ketamine has emerged as a promising treatment for chronic pain, effectively alleviating conditions like neuropathic pain and complex regional pain syndrome (CRPS). In a review of multiple studies, ketamine demonstrated significant pain relief in over 70% of patients suffering from these conditions. Traditional opioid treatments often fail to provide adequate relief and carry risks of dependency. This alternative approach highlights ketamine’s potential as a safe and effective option in pain management, with ongoing exploration into its mechanisms and clinical applications.
Abstract
Chronic pain is a pervasive and debilitating condition that affects millions of individuals worldwide. Traditional methods of pain management, incl...
Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
OpenAlex – September 17, 2025
Summary
A single dose of psilocybin, a psychedelic compound, provided sustained pain relief in a model of chronic nerve injury pain in mice. This finding, crucial for Pain Mechanisms and Treatments, showed psilocybin's effects were partly mediated by 5-HT 2A receptors. Furthermore, this alkaloid significantly boosted the pain-reducing potential of gabapentin, a common drug. These initial drug studies suggest psilocybin could offer a valuable new approach for managing chronic pain, potentially by establishing lasting changes in neural processing.
Abstract
Abstract Chronic pain states are challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin can prod...
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Br J Pain – September 04, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) at 15 µg significantly blunted pain perception, offering a potential new avenue for pain management. A randomised, placebo-controlled investigation with 40 healthy volunteers found participants experienced a 25% reduction in pain intensity. This suggests a single low dose of LSD can alter how the brain processes discomfort. The findings highlight the therapeutic potential of carefully administered psychedelics, warranting further exploration into their mechanisms and broader applications for chronic pain conditions.
Abstract
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
Psychoactives – September 01, 2025
Summary
A patient suffering chronic pain and recurrent depression experienced significant relief following four sessions of psilocybin-assisted psychotherapy. This intervention, guided by a psychotherapist, markedly reduced pain's daily impact, increased pain acceptance, and improved quality of life, alongside alleviating depressive symptoms. This promising case, bridging Medicine, Psychology, and Psychiatry, highlights psilocybin’s potential. Psilocybin, an alkaloid studied in Chemical synthesis and alkaloids, shows growing therapeutic promise within Psychedelics and Drug Studies, contributing to Complementary and Alternative Medicine Studies for chronic pain.
Abstract
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatmen...
The Future of Pain Management.
Neurologic clinics – August 01, 2025
Summary
Pain isn't just physical; it's a complex sensory, emotional, and cognitive experience. A comprehensive review reveals a promising future for pain management. Advances in treatment algorithms, novel pain medication like psychedelics, and noninvasive neuromodulation offer exciting new pain interventions. This heralds significant potential for effective pain treatment, transforming care for both acute pain and chronic pain.
Abstract
This article explores the complexities of pain management, highlighting the multidimensional nature of pain, which encompasses affective, cognitive...
State of the art in EEG signal features of mindfulness-based treatments for chronic pain.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology – August 01, 2025
Summary
Mindfulness-based treatments show promise for chronic pain management, with EEG data revealing significant insights. Out of 131 reviewed papers, only four met criteria for analysis, highlighting the topic's early exploration. Notably, higher baseline theta power correlated with improved depression outcomes in patients undergoing mindfulness interventions. Additionally, EEG source analysis indicated that emotional response regions are actively engaged during treatment. This suggests that EEG monitoring could enhance tailored non-pharmacological approaches, improving patient outcomes and identifying those who may benefit most from mindfulness strategies.
Abstract
A systematic review of electroencephalographic (EEG) correlates of Mindfulness- based treatment for chronic pain is presented. Recent technological...
Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation.
The journal of pain – July 21, 2025
Summary
Living with chronic pain often reshapes identity, hindering one's ability to find meaning. A new perspective suggests psilocybin could help individuals reframe their experience, fostering meaning-making and reducing self-pain enmeshment. By modulating self-perception, this approach aims to enhance engagement in rehabilitation, offering a novel path to improved physical and psychological well-being for those with chronic pain.
Abstract
Those living with chronic pain and comorbid functional disabilities are often confronted by a physically and emotionally transformative experience,...
Emerging Use of Low-Dose Ketamine for Pain Management Beyond the ICU.
Journal of pain & palliative care pharmacotherapy – July 20, 2025
Summary
Ketamine, traditionally for critical care, is now a powerful opioid alternative for pain management. A community hospital successfully implemented a low-dose ketamine infusion protocol on inpatient floors. This offers effective relief, especially for post operative pain, demonstrating a safe, valuable new model for broader adoption of ketamine in pain management.
Abstract
Pain management is a critical challenge in healthcare as acute and chronic pain affect millions of individuals globally. Opioid-based therapies tha...
Ayahuasca, Pain, and Inflammation: A Systematic Review of Preclinical Studies
Psychoactives – July 15, 2025
Summary
Ayahuasca shows significant potential in pain relief and inflammation reduction, with 29 out of 1,535 reviewed studies confirming its benefits. Specifically, ayahuasca's compounds, particularly harmine, exhibit notable antinociceptive effects and influence cytokine levels—reducing pro-inflammatory markers while increasing anti-inflammatory ones. These findings highlight ayahuasca's role in medicine as a promising treatment for chronic pain and inflammation, leveraging its unique biochemical properties linked to tryptophan metabolism and psychoactive components. Further exploration could enhance understanding and application in treating brain disorders.
Abstract
Pain is a protective mechanism that can be classified into acute and chronic types. Ayahuasca is a psychoactive brew rich in dimethyltryptamine or ...
Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.
Journal of affective disorders – July 15, 2025
Summary
Regular opioid use may reduce the effectiveness of placebo treatments for depression, while ketamine's antidepressant effects remain strong. This finding emerged from analyzing surgical patients with depression, some taking opioids. Those on opioids showed weaker responses to placebo treatments, but ketamine's mood-lifting benefits weren't affected. The results suggest opioid medications might interfere with the brain's natural ability to benefit from placebo effects in depression treatment.
Abstract
The endogenous opioid system is thought to play a role in the placebo antidepressant response. A recent trial comparing the rapid antidepressant ef...
A Randomized Controlled Trial of Intraoperative Ketamine for Acute Postsurgical Pain after Breast Cancer Surgery: The Moderating Effect of Baseline Temporal Summation of Pain.
Anesthesiology – July 14, 2025
Summary
Some patients feel more pain after surgery due to how their nervous system processes it. A trial explored if intraoperative ketamine could help. While not universally effective for breast surgery pain, it significantly reduced pain in patients showing a higher tendency for central sensitization. This suggests tailoring pain management to individual patient characteristics for better outcomes.
Abstract
Activation of nociceptive pathways by surgical trauma can induce central sensitization, which is associated with greater pain severity and persiste...
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models
OpenAlex – July 07, 2025
Summary
Despite hopes that the hallucinogen psilocybin could be a future medicine for chronic pain, new pharmacology research suggests otherwise. Comprehensive Psychedelics and Drug Studies, testing the alkaloid psilocybin across a range of doses in multiple mouse models for acute pain and chronic inflammatory, neuropathic, or musculoskeletal pain, reveal it is not directly analgesic. This challenges the idea that its potential therapeutic benefits stem from direct pain relief, distinguishing it from traditional analgesic agents or anesthesia. Its Neurotransmitter Receptor Influence on Behavior might be key, rather than direct pain modulation.
Abstract
Abstract The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical da...
Multiday intravenous ketamine infusion therapy for the management of central sensitisation syndrome secondary to chronic chemotherapy-induced peripheral neuropathic pain.
BMJ case reports – July 03, 2025
Summary
Ketamine infusion therapy is increasingly recognized for chronic Pain relief. In a compelling Neurology case, a man with severe Pain (neurology) from chemotherapy-induced Peripheral nerve disease, complicated by central sensitization, received multiday ketamine. This treatment yielded significant, sustained improvement in his function and Pain control, demonstrating ketamine's potential for complex chronic Pain conditions.
Abstract
Ketamine infusion therapy is increasingly being used as an effective treatment for chronic pain syndromes, including central sensitisation syndrome...
Beyond prohibition: A public health analysis of naturalistic psychedelic use
Journal of Psychedelic Studies – July 03, 2025
Summary
Naturalistic psychedelic use, outside clinical settings, appears to significantly reduce depression, anxiety, PTSD, and even interpersonal violence, while boosting well-being and social connection. A review of 104 peer-reviewed articles reveals these public health benefits across diverse populations. Though adverse effects can occur, they are typically brief and linked to factors like high doses or psychological vulnerability. This comprehensive analysis, spanning psychology and criminology, indicates current drug policies are outdated. An evidence-informed public health approach for psychedelics is urgently needed.
Abstract
Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehe...
Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.
CNS spectrums – June 30, 2025
Summary
Once primarily an anesthetic, ketamine is now recognized for its remarkable rapid antidepressant effects, particularly in severe depression. This versatile agent, despite its challenges as a recreational drug, offers a novel approach to mood regulation. Its medical utility extends beyond anesthesia to pain management and potential anti-inflammatory benefits, showcasing its significant positive impact and evolving role in modern medicine.
Abstract
Ketamine, originally synthesized in 1962, has gained increasing attention due to its rapid and sustained antidepressant effects in treatment-resist...
Ketamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks.
Molecules (Basel, Switzerland) – June 30, 2025
Summary
Originally an anesthetic, ketamine is now revolutionizing medicine. It effectively treats severe pain and offers rapid relief for depression, even in resistant cases. Surprisingly, ketamine also shows promise in tackling addiction by promoting brain plasticity. This versatile drug is transforming approaches in mental health and pain management.
Abstract
Ketamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to...
Sex and Age Differences in Ketamine Efficacy and Safety in Chronic Pain Alleviation.
Journal of clinical medicine – June 16, 2025
Summary
Ketamine's effectiveness in treating chronic refractory pain and depression appears consistent across different patient groups. A year-long study of 585 individuals found that repeated ketamine administrations offered similar relief from pain, anxiety, and depression for both sexes and various ages. While women experienced slightly more side effects, the overall positive impact on refractory pain and mood remained consistent.
Abstract
Background: Ketamine use for chronic pain and depression has increased worldwide, but sex differences in its efficacy and safety have been little s...
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives
ACS Chemical Neuroscience – June 06, 2025
Summary
Millions worldwide suffer chronic pain, often with depression. Neuroscience and Drug Studies reveal classic psychedelics, like psilocybin and LSD, which are alkaloids, offer a compelling new frontier in Medicine. These substances, influencing neuroplasticity and primarily acting on serotonin 5-HT2A receptors, appear to modulate pain perception and mood. Early evidence from case studies and preclinical research suggests they may alleviate conditions such as migraines and fibromyalgia. While exact mechanisms require further study, rigorous trials are vital to establish their therapeutic role in Psychology and Medicine, potentially guided by psychotherapists for mood aspects.
Abstract
Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for inno...
Enhancing interoceptive awareness in chronic pain and opioid misuse via mindfulness-oriented recovery enhancement.
Drug and alcohol dependence – June 02, 2025
Summary
Many individuals with substance use issues report altered body awareness. For those with chronic pain, lower interoceptive awareness was specifically linked to higher opioid misuse. A Mindfulness-based program significantly enhanced interoception, successfully reducing opioid misuse over nine months. This suggests that boosting interoceptive awareness is a promising strategy for managing chronic pain and addressing opioid misuse.
Abstract
Individuals with substance use disorders often report altered interoceptive awareness of internal bodily signals. However, it is unclear whether th...
Ketamine infusion for pain control in severely injured patients: Results of a randomized controlled trial.
The journal of trauma and acute care surgery – June 01, 2025
Summary
In the quest for better pain management after severe injury, ketamine shows unexpected results. A rigorous trial at a major trauma center explored whether this alternative medication could reduce reliance on opioids in patients with serious injuries. Despite high hopes, low-dose ketamine infusions didn't decrease opioid use or improve pain scores compared to placebo. This challenges current assumptions about ketamine's role in trauma care.
Abstract
Opiate-based pain regimens remain the cornerstone of pain management following traumatic injury, but issues related to opioids have driven research...
Neurotransmitter-related functional connectivity changes in serotonin and dopamine systems after mindfulness in medication overuse headache.
Cephalalgia : an international journal of headache – June 01, 2025
Summary
Mindfulness practice can positively reshape brain chemistry, offering new hope for chronic pain. In individuals with medication overuse headache, brain scans using resting state fMRI revealed significant improvements. After a year, those practicing mindfulness showed enhanced serotonin and dopamine connections in brain regions crucial for pain, emotion, and addiction. This suggests mindfulness beneficially impacts these systems, aiding chronic pain management.
Abstract
Background/HypothesisMindfulness practice has gained attention in managing chronic migraine with medication overuse headache (CM-MOH), showing clin...
Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2025
Summary
Remarkably, psychedelics show promise for unique women’s health challenges. This review highlights their potential in reproductive health, noting how they interact with female hormones. Findings suggest benefits for conditions like postpartum depression and other issues, though caution is advised during pregnancy. These compounds could offer novel avenues for enhancing women’s well-being.
Abstract
In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, ...
Ketamine Cystitis Following Ketamine Therapy for Treatment Resistant Depression – Case Report
BJPsych Open – June 01, 2025
Summary
A 28-year-old woman developed severe bladder inflammation (ketamine-induced cystitis) while receiving therapeutic ketamine for depression, the first reported case in this context. This condition, known to affect over 25% of regular recreational ketamine users, can cause symptoms from urgency and pain to chronic kidney failure. The finding underscores a critical concern for therapeutic ketamine's emerging role. Prompt diagnosis and discontinuing the medication are crucial to prevent lasting urinary tract damage.
Abstract
Aims: Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly...
A Review of Treatment Modalities for Comorbid Neuropathic Pain and Depression.
Journal of integrative neuroscience – May 26, 2025
Summary
People experiencing chronic nerve pain are 3x more likely to develop depression, highlighting a crucial link between these conditions. New evidence reveals that treating both neuropathic pain and depression simultaneously yields better outcomes than addressing each separately. Multiple treatment approaches, from nerve-targeting medications to brain stimulation techniques, show promise in managing this challenging co-morbidity. The most effective solutions combine physical and behavioral therapies with targeted medications.
Abstract
Over the past years, a number of clinical and preclinical investigations have been documented, suggesting treatment strategies and pharmaceuticals ...
Ergotamine enhances circadian amplitude and diurnally mitigates nitroglycerin-induced mechanical hypersensitivity.
The journal of headache and pain – May 23, 2025
Summary
Remarkably, a common migraine treatment, Ergotamine, significantly boosts the amplitude of the body's internal clock. Using Per2:lucSV fibroblasts and animal models, it was found that this Ergot derivative strengthens the Circadian transcriptional-translational feedback loop. This positive effect not only enhances rhythmicity but also improved pain sensitivity in a headache model, specifically when administered during the daytime, suggesting a chronotherapeutic benefit.
Abstract
Cluster headache and migraine have a circadian timing of attacks and are linked to the trigeminovascular system. Recently the trigeminal ganglion w...
Effectiveness of non-surgical interventions for patients with chronic sciatica: A systematic review with network meta-analysis.
The journal of pain – May 13, 2025
Summary
Relief for chronic sciatica sufferers: Multiple non-surgical interventions show promise in managing leg pain. Spinal manipulation, exercise combined with neural mobilization, and targeted injections demonstrated significant pain reduction. Physical therapy and specialized injection treatments offered lasting functional improvements, giving patients more options beyond surgery.
Abstract
The objective of the study was to investigate the comparative effectiveness of non-surgical interventions for adults with chronic sciatica. EMBASE,...